The Rise and Fall of a Revolutionary Drug

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

One of the best drug launches in history has become one of the fastest run downs.

Approved in May 2011, Vertex Pharmaceuticals' (NASDAQ: VRTX  ) hepatitis C drug Incivek hit $457 million in sales in its second full quarter on the market. Many drugs never hit $457 million in annual sales at their peak.

Less than two years later, sales are down to $86 million in the most recent quarter. You can't say I didn't warn you.

Ironically, what made Incivek so popular to begin with is also what caused the crash. Hepatitis C is a slowly developing disease, so there's a limited downside to patients waiting a few years to be treated if the virus isn't doing much damage to the liver yet.

Doctors could see that Incivek and Merck's (NYSE: MRK  ) Victrelis were working well in clinical trials, so they cut back on the prescribing the standard of care at the time -- Roche's Pegasys or Merck's Pegintron with a generic called ribavirin -- because they only cured about half the patients and make many people feel like they have the flu.

Once Incivek was approved, the warehoused patients were prescribed Incivek, which had a little better data than Merck's Vicrelis, and sales skyrocketed.

Rinse and repeat
But then doctors heard about the next generation of drugs and started warehousing again. Doctors are going to prescribe Johnson & Johnson's (NYSE: JNJ  ) simeprevir¬†and Gilead Sciences' (NASDAQ: GILD  ) sofosbuvir, which both look like they're going to get approved this year after getting unanimous endorsements from their respective advisory committees. The large number of drugs in clinical trials also siphoned off some patients.

Vertex has seen the writing on the walls, so the biotech is cutting 370 positions, about 15% of its workforce, to conserve cash while it ramps up its cystic fibrosis business. Vertex also has a next-generation hepatitis C drug, VX-135, but it'll take a few years to get approved -- if side effects don't kill it first -- so it doesn't make sense to keep the hepatitis C sales force on the payroll.

All those workers can find new homes at Johnson & Johnson or Gilead Sciences. At least until doctors start warehousing again.

These two biotechs should have longer legs
Like Vertex's revolutionary drugs for hepatitis and cystic fibrosis, Motley Fool analysts have found two drugmakers with a groundbreaking technology helping cancer patients. In the brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about the new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Read/Post Comments (2) | Recommend This Article (5)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 29, 2013, at 6:56 PM, HighlandsFlash wrote:

    I completed this regimine of Incivik, ribavirin, and Pegasys (interferon). It was the worse and longest six months in my life. The side affects were disabling. It was so bad my Doctor apologized after I was done and actually told me, "there is no way I could have made it through the treatment." The "flu like" symptoms were like the worse one I've ever had and it lasted the entire six months. Zofran, nausea drugs for chemo patients, helped a lot but not completely. During the initial three months you have to take everything with 20 grams of fat THREE times a day so you gain a lot of weight.

    If you know anyone considering this treatment tell them to wait as better things are on the horizon. This treatment takes a very strong person to even consider going through it.

  • Report this Comment On October 30, 2013, at 5:59 PM, neelvk wrote:

    My father passed away in 2001 due to Hep C. I wish he had had a chance to try these drugs...

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2704298, ~/Articles/ArticleHandler.aspx, 9/28/2016 8:11:58 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,339.24 110.94 0.61%
S&P 500 2,171.37 11.44 0.53%
NASD 5,318.55 12.84 0.24%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 4:00 PM
VRTX $88.84 Down -0.28 -0.31%
Vertex Pharmaceuti… CAPS Rating: ****
GILD $78.97 Down -0.28 -0.35%
Gilead Sciences CAPS Rating: *****
JNJ $119.39 Up +0.17 +0.14%
Johnson and Johnso… CAPS Rating: *****
MRK $63.30 Up +0.73 +1.17%
Merck and Co. CAPS Rating: ****